ARTICLE | Clinical News

Sunovion gets FDA approval for Lonhala Magnair COPD treatment

December 8, 2017 4:13 AM UTC

The Sunovion Pharmaceuticals Inc. subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA approved Lonhala Magnair glycopyrrolate (SUN-101/eFlow) as a long-term maintenance treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Sunovion expects to launch the product early next year.

The company said this is FDA's first approval of a nebulized long-acting muscarinic antagonist (LAMA) to treat COPD...